WVE: Wave Life Sciences, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-10-27 | New 13G stake | BlackRock, Inc. | 6.80% | +6.80 pts | SEC |
| 2026-10-27 | Fell below 5% | BlackRock, Inc. | 0.00% | SEC | |
| 2026-08-11 | 13D amendment | RA Capital Management, L.P. | 16.80% | SEC |
Institutional ownership (Q2 2026)
1 institutions reported holding $2.49M of Wave Life Sciences, Inc. on Form 13F (0 the quarter before). 1 opened a new position and 0 sold out. Shares held by institutions: new.
| Largest holders | Shares | Value |
|---|---|---|
| KENNEDY CAPITAL MANAGEMENT LLC | 429,121 | $2.49M |
Clinical trial readouts
2 Phase 2 or 3 trials by Wave Life Sciences, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-10 (est.) | WVE-N531 | Duchenne Muscular Dystrophy | Phase 1/2 | 25 | Enrollment complete | NCT04906460 |
| 2027-09 (est.) | WVE-006 | Alpha-1 Antitrypsin Deficiency | Phase 1/2 | 48 | Recruiting | NCT06405633 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.